AQUA BIO TECHNOLOGY ASA – RESULT OF PRIVATE PLACEMENT – PROPOSED CHANGES IN BOARD OF DIRECTORS

by | Jan 7, 2019

Reference is made to the stock exchange notice by Aqua Bio Technology ASA (the
"Company") on 4 December 2018 regarding, inter alia, a private placement with
gross proceeds of up to NOK 15 million through issuance of new shares at a
subscription price of NOK 2.50 per share (the "Private Placement"). The
investors in the Private Placement will also receive one (1) warrant per share
applied for and allocated in the Private Placement.

The application period in the Private Placement ended on 3 January 2019 at
16.30 CET. At the end of the application period, the Company had received
applications of approximately NOK 11.735 million in the Private Placement.

The Company's board of directors (the "Board") has now allocated shares and
warrants in the Private Placement, which implies that the Board will propose
that the general meeting to be held on 7 January 2019 resolves issuance of
4,694,000 new shares and 4,694,000 new warrants related to the Private
Placement.

The Company's obligation to complete the Private Placement is conditional upon
the following:

  * The Company's extraordinary general meeting resolving the proposed share
    capital decrease, the Private Placement and the issuance of the warrants;
  * Receipt of payments for share deposits in the Private Placement; and
  * Due registration of the proposed share capital decrease, the share capital
    increase pertaining to the Private Placement and the resolution to issue
    warrants in the Norwegian Register of Business Enterprises.


The Board will further propose that the general meeting that Roger Hofseth is
elected as new Board member, in addition to the existing Board members. Roger
Hofseth is the chief executive officer and founder of Hofseth BioCare ASA, and
one of the largest shareholders in the Company.

For further information, please call Arvid Lindberg, Head of Sales & Marketing,
telephone +47 9824 5410 or arvid@aquabiotech.no.

Aqua   Bio  Technology  (ABT)  is  developing  and  commercializing  sustainable
biotechnology  for use  in skin  care products.  ABT's cosmetics ingredients are
highly   effective   and  they  provide  the  cosmetics  industry  with  natural
alternatives  to traditional ingredients. ABT is also marketing and distributing
natural   skin  care  products  developed  by  partners  towards  consumers  and
professional  users. Aqua Bio  Technology is listed  on the Axess  market of the
Oslo Stock Exchange.

This information is subject to the disclosure requirements pursuant to section
5-12 of the Norwegian Securities Trading Act.